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Background. Cell signaling via Toll-like receptors (TLRs) leads to synovial inﬂammation in rheumatoid arthritis (RA). We aimed
to assess eﬀects of TLR2 and TLR4 stimulation on proinﬂammatory cytokine production by peripheral blood mononuclear cells
(PBMCs) from patients with recent-onset RA, osteoarthrosis (OA), and healthy control (HC). Methods. PBMCs were stimulated
withLPS,biglycanandcytokinemix.CytokineswereanalyzedinsupernatantswithELISA.Expressionoftoll-likereceptorsmRNA
in leukocytes was analyzed using real-time qPCR. Results. PBMCs from RA patients spontaneously produced less IL-6 and TNFα
than cells from OA and HC subjects. LPS increased cytokines’ production in all groups. In RA patients increase was dramatic
(30 to 48-fold and 17 to 31-fold, for respective cytokines) compared to moderate (2 to 8-fold) in other groups. LPS induced
15-HETE generation in PBMCs from RA (mean 251%) and OA patients (mean 43%), although only in OA group, the increase
was signiﬁcant. TLR2 and TLR4 gene expressions decreased in response to cytokine mix, while LPS enhanced TLR2 expression
in HC and depressed TLR4 expression in OA patients. Conclusion. PBMCs from recent-onset RA patients are overresponsive to
stimulation with bacterial lipopolysaccharide. TLR expression is diﬀerentially regulated in healthy and arthritic subjects.
Copyright © 2008 M. L. Kowalski et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Rheumatoid arthritis (RA) is a complex disease of yet
unknown pathogenesis. Several factors have been proposed
as potential triggers of inﬂammatory response associated
with RA rheumatoid arthritis, including microbes and
their products [1, 2]. Products of invading microbes may
activate inﬂammatory cells via Toll-like receptors (TLRs),
which leads to immune and inﬂammatory responses. TLRs
activation has been linked to the pathogenesis of rheumatoid
arthritis, and both TLR-2 and TLR-4 are potentially critical
receptors in the initiation and perpetuation of the inﬂam-
matory cycle in arthritis [3]. It has been also demonstrated
that endogenous TLR4 ligands (e.g., heat shock proteins and
extradomainAﬁbronectin)arehighlyexpressedinthejoints
of patients with RA [4–6]. Toll-like receptors are present on
tissue synoviocytes but also on peripheral blood monocytes
which are recruited to the site of inﬂammation and are
involved in the pathogenesis of synovial inﬂammation [7–
10]. Recent studies described higher expression of TLR4 in
leucocytes from patients with ankylosing spondylitis and
increasedexpressionofTLR2andTLR4receptorsincartilage
lesions occurring during OA suggesting that abnormal TLR
signaling may also be involved in the pathogenesis of
rheumatologic conditions other than rheumatoid arthritis
[11, 12].
IL-6 and TNFα as well as IL-1 family cytokines and
chemokines have been markedly elevated in synovial ﬂuid
and synovial membranes from patients with RA, but not
in patients with OA [13–15]. Moreover, in sera of RA
patients spontaneous IL-1, -6, -8, -18, and TNFα production
are signiﬁcantly higher than in healthy individuals and2 Mediators of Inﬂammation
Table 1: Clinical characteristic of patients.
Rheumatoid arthritis Osteoarthrosis Healthy control
Female/male 6 /1 7/0 6/1
Age in years (median; range) 56 (35–68) 59 (53–75) 32 (27–55)
aCCP in IU/mL (mean ± SD) 68,76 ± 47,17 4,02 ± 5,79 Not done
CRP mg/l (mean ± SD) 12 ± 66 ± 0N o t d o n e
DAS28 (median; min-max) 4,2 (1,96–6,27) n/a n/a
anti-TNFαtreatmentdecreaseslocalandsystemicexpression
of TLR2 and TLR4 receptors [16, 17].
Earlier studies documented that peripheral blood mo-
nonuclear cells from RA patients generate signiﬁcantly more
inﬂammatory cytokines and chemokines, although the dif-
ference between patients with new onset and established
rheumatoid arthritis could not be clearly determined [18–
21].
We aimed to assess the eﬀect of Toll-like receptors 2 and
4 stimulation on production of inﬂammatory cytokines and
generation of 15-HETE by PBMCs from patients with newly
diagnosed RA in comparison with patients with osteoarthro-
sis and healthy controls. In addition, we sought to determine
in what way the stimulation of TLRs (exempliﬁed by TLR4
stimulationinourexperiments)onleucocytes’surfacemight
aﬀect expression of Toll-like receptors themselves on the
mRNAlevel.Finally,weinvestigatedtheinﬂuenceleucocytes’
stimulation with mix of strong proinﬂammatory cytokines
on expression of TLR2 and TLR4 at mRNA level.
2. METHODS
2.1. Patients
Twenty one subjects were recruited to the study, including
7 patients with rheumatoid arthritis (RA), 7 patients with
osteoarthrosis (OA) and 7 healthy control (HC) subjects.
RA and OA were diagnosed according to American College
of Rheumatology guidelines [22]. Severity of rheumatoid
arthritis was assessed employing the composite 28-joint
disease activity score (DAS28). Although no gold standard
forassessmentofRAactivityexists,theDAS28scorehasbeen
adopted by European rheumatologists as a daily practice
tool [23, 24]. DAS28 scoring provides a numeric index, in
which a score >5.1 implies high-disease activity, a score <3.2
indicates low disease activity, and a score <2.6 indicates
remission. Patients with RA were newly diagnosed and
had not received disease-modifying antirheumatic drugs
(DMARDs) before inclusion into the study and presented
with moderate disease activity according to DAS28 (mean
index ± SD; 4,31 ± 1,32). Additional parameters used
for clinical characterization of patients included anti-cyclic
citrullinatedpeptideantibodies(aCCPs)aswellasC-reactive
protein (CRP) serum concentration measurements. Serum
aCCP presence is a marker of early phase RA. They are more
speciﬁc as a diagnostic tool than RF and are considered a
good predictor of severe erosive disease [25]. CRP elevation
is the most useful index of the acute phase response being
speciﬁc, sensitive, and rising rapidly during 6 to 10 hours
after the initiation of an inﬂammatory process [26].
T h ea C C P sw e r ed e t e c t e di na l lR Ap a t i e n t sa n di nn o n e
of patients without RA. The concentration of C-reactive
protein (CRP) in serum was increased in RA compared
to OA patients. Control group consisted of young healthy
volunteers. A clinical characteristic of patients is presented
in Table 1.
All participants gave their written consent after being
fully informed about the purpose of the study, which was
previously approved by Local Bioethics Committee of the
Medical University of Lodz.
2.2. Puriﬁcationofperipheralbloodmononuclearcells
Blood samples (27mL per patient) were collected by
peripheralvenipuncture.Peripheralbloodmononuclearcells
were puriﬁed by centrifugation on Histopaque-1077 (Sigma
Aldrich, St. Louis, Mo, USA). Brieﬂy, peripheral blood
was diluted with phosphate buﬀered saline and carefully
layered onto Histopaque-1077 and centrifuged at 400g for
30 minutes at room temperature. The opaque interface was
washed three times and ﬁnally resuspended at a density
of 106 cells/ml in RPMI-1640 medium (Sigma Aldrich,
St. Louis, Mo, USA) supplemented with 10% heat inacti-
vated Fetal Bovine Serum (Sigma-Aldrich, St. Louis, Mo,
USA), antibiotic (penicillin, streptomycin), and antimycotic
(amphothericin B) solution (Sigma Aldrich, St. Louis, Mo,
USA).
2.3. Cellstimulation
PBMCs were incubated with LPS at a concentration of 1,
10, and 100ng/mL, biglycan (BGN) at concentrations of
0.1, 1, and 10ng/mL and with cytokine mix (including
10ng/mL of IL-1, 10ng/mL IL-6, and 100ng/mL TNFα)f o r
24 hours. After centrifugation, supernatants were harvested
and analyzed for IL-6 or TNFα using ELISA kits (Bender
MedSystems Inc., Burlingame, Calif, USA).
2.4. RNAisolationandreversetranscription
Total RNA was isolated from leukocytes using Total RNA
Mini kits (A&A Biotechnology, Gdynia, Poland) in accor-
dance with manufacturer’s instructions. Total RNAs were
converted to complementary DNA (cDNA) by random
priming with M-MLV reverse transcriptase (Promega,M. L. Kowalski et al. 3
Table 2: Spontaneous and stimulated IL-6 production by peripheral blood mononuclear cells from patients with rheumatoid arthritis
(RA), osteoarthrosis(OA), and healthy controls (HC); median values; P<. 05
∗—signiﬁcantly diﬀerent from nonstimulated; #—signiﬁcant
diﬀerence between RA and HC ∧—signiﬁcant diﬀerence between RA and OA.
Nonstimulated Stimulus
LPS 1ng/mL LPS 10ng/mL LPS 100ng/mL BGN 0,1ng/mL BGN1#ng/mL BGN#10ng/mL
Group of subjects concentration of IL-6 (ng/mL)
RA 0,56#∧ 22,87∗ 42,95∗∧ 46,72∗ 2,0∧ 1,24#∧ 1,55#∧
OA 27,2 43,6∗ 88,47∗ 75,1∗ 22,6 33,01 23,0






























Figure 1: Individual changes in IL-6 concentration in the super-
natants of human leucocytes culture after stimulation with LPS
at 100ng/mL; log10 scale; HC-healthy controls, OA-osteoarthrosis,
RA-rheumatoid arthritis; ∗P<. 03, Wilcoxon’s test.
Madison, Wis, USA). After reverse transcription, cDNA was
stored at −20◦C for further analysis.
2.5. Quantitativereal-timePCR
Quantitative real-time PCR was performed using ABI Prism
7000SequenceDetectionSystem(AppliedBiosystems,Foster
City, Calif, USA). We used iTaq SYBR Green Supermix With
ROX (Bio-Rad Laboratories, Inc., Hercules, Calif, USA) as
s u g g e s t e db yt h em a n u f a c t u r e r .I nb r i e f ,r e a c t i o n sw e r ec a r -
riedoutin20μl containing 1μlcDNA, 10μl2× SYBRGreen
supermix, and 200 nM of each speciﬁc primer. The cycling
parameters were 3 minutes at 95◦C followed by 45 cycles of
denaturationat95◦Cfor15secondsandannealing/extension
at 60◦C for 45 seconds. For relative quantiﬁcation, an n-
fold diﬀerential expression has been calculated using 2−ΔΔCt
method. Ampliﬁcation of each target gene (TLR2 and TLR4)
was normalized to that of β-actin (housekeeping gene).
Ampliﬁed products were checked for their correct size by
means of agarose gel electrophoresis. Speciﬁc primers used
for TLR2, TLR4, and β-actin ampliﬁcation were described
previously by Guti´ errez-Ca˜ nas et al. [27] and their sequences
were as follows: TLR2 sense 5 GGA AGA ATC CTC CAA
TCA GGC 3 ; TLR2 antisense 5 CTT CTG TGA GCC CTG
AGG GA 3 ; TLR4 sense 5 AGC CAC GCA TTC ACA GGG
3 ; TLR4 antisense 5 CAT GGC TGG GAT CAG AGT CC 3 ;
β-actin sense 5 AGA AGG ATT CCT ATG TGG GCG 3 ; β-




Nonstimulated PBMCs from RA patients demonstrated a
signiﬁcantly lower production of IL-6 as compared to OA
patients (median value 48 times lower) and to control
subjects (median value 45 times lower) (Table 2). Stimu-
lation with LPS, an agonist for TLR4 receptors, resulted
in signiﬁcant increase in IL-6 production in all 3 groups.
However, in cells from patients with RA, the increase was
dramatic (median 30, 48, and 44 folds over baseline after
1, 10, and 100ng/mL of LPS, resp.) as compared to only
moderate (2 to 4 folds) increase observed in cells from
patients with OA or healthy subjects (Figure 1).
Incubation of cells with biglycan, the agonist for TLR2
receptors,resultedinsmallandnonsigniﬁcantincreaseinIL-
6 production in both RA patients (after all biglycan concen-
trations) and AO patients (only after biglycan at 1ng/mL).
In healthy subjects, insigniﬁcant increases were observed
following2highestconcentrations,andsmalldecrease(22%)
was noticed after the lowest biglycan concentration.
3.2. TNFαproductionbyPBMCsinresponseto
stimulationwithLPSandbiglycan
Nonstimulated PBMCs from RA patients generated sig-
niﬁcantly less TNFα as compared to OA patients (mean
12 times less) and control subjects (mean 10 times less)
(Table 3). Incubation with LPS induced an increase in TNF-
α production in all 3 groups. However, similarly to IL-6,
the increase in TNFα production was signiﬁcantly more
intense after LPS at 10 and 100ng/mL (resp., 31 and 29
folds over the baseline) as compared to that observed in
cells from patients with OA (mean 3 to 8 folds increase for
diﬀerentLPSconcentrations)orhealthysubjects(mean4-to
7-fold increase for diﬀerent LPS concentrations) (Figure 2).
Stimulation with biglycan induced a signiﬁcant increase in
TNFα production only in PBMCs from healthy subjects in
response to the highest concentration.
3.3. 15-HETEgenerationbyPBMCsinresponseto
stimulationwithLPSandbiglycan
15-HETE was generated by unstimulated PBMCs cells from
both RA and OA patients in similar amounts. Stimulation
with LPS increased 15-HETE generation in 5 RA patients4 Mediators of Inﬂammation
Table 3: Spontaneous and stimulated TNFα production by peripheral blood mononuclear cells from patients with rheumatoid arthritis
(RA), osteoarthrosis (OA), and healthy control (HC); P<. 05
∗—signiﬁcantly diﬀerent from nonstimulated; #—signiﬁcant diﬀerence
between RA and HC ∧—signiﬁcant diﬀerence between RA and OA.
Nonstimulated LPS 1ng/mL LPS 10ng/mL LPS 100ng/mL BGN 0,1ng/mL BGN 1ng/mL BGN 10ng/mL
Group of subjects Concentration of TNFα (ng/mL)
RA 0,05∧#0 , 7 2 ∧#2 , 0 2 ∗ 2,84∗ 0,1∧# 0,26 0,07∧#
OA 0,59 4,71∗ 2,48∗ 2,62∗ 0,84 0,45 0,71
HC 0,49 2,59∗ 1,98∗ 1,94∗ 0,63 0,65 0,68∗
Table 4: Relative quantiﬁcation of the TLR2 and TLR4 mRNA
expressioninPBMCsfrompatientswithrheumatoidarthritis(RA),
osteoarthrosis (OA), and healthy control (HC).
(a) Target gene expression is normalized to housekeeping gene expres-
sion and presented as n-fold of the expression in HC group (2−ΔΔCT).
∗denotes signiﬁcant diﬀerence in expression comparing with HC (P<
.03).
Nonstimulated Cytokine mix LPS
TLR2
HC 1 1 1
RA 2.045 2.915 0.036
OA 1.218 1.66 0.074
TLR4
HC 1 1 1
RA 0.008∗ 0.225 0.0009∗
OA 0.004∗ 0.044∗ 0.00002∗
(b) Target gene expression after stimulation with cytokine mix or
LPS is normalized to housekeeping gene expression and presented as
n-fold of the expression in non stimulated cells from patients from
every group (2−ΔΔCT). Signiﬁcant diﬀerences in expression compared to
nonstimulated cells are marked with ∗P<0.02; #P<0.01.
Nonstimulated Cytokine mix LPS
TLR2
HC 1 0.268 17.753∗
RA 1 0.382 0.316
OA 1 0.365# 1.071
TLR4
HC 1 0.00006∗ 0.1
RA 1 0.212 1.498
OA 1 0.093# 0.092∗
(range 27–320%) while decreased in 2 patients (32% and
34%, resp.). In OA patients, LPS induced a signiﬁcant (P<





Expression of TLR2 mRNA in nonstimulated, cytokine mix-
stimulated, or LPS stimulated cells was similar in RA, OA






























Figure 2: Individual changes in TNFα concentration in the
supernatants of human leucocytes culture after stimulation with
LPS100ng/mL;log10 scale;HC-healthycontrols;OA-osteoarthritis;

































Figure 3: Changes in 15-HETE release into mononuclear cells
supernatants after stimulation with 100ng/mL LPS in individual
patients OA-osteoarthritis; RA-rheumatoid arthritis; ∗p<. 01.
mRNA in nonstimulated as well as in LPS or cytokine-mix
stimulated cells was similar in patients with RA and OA,
although in both groups, it was signiﬁcantly lower than in
cells from HC.
Incubation with cytokine mix tended to decrease both
TLR2 and TLR4 expressions although the decrease was
signiﬁcant for both receptors in OA patients and for TLR4 in
HC subjects (Table 4(b)). TLR2 gene expression was signiﬁ-
cantly increased by LPS in healthy controls, while signiﬁcantM. L. Kowalski et al. 5
suppressionofTL4mRNAexpressionwasobservedafterLPS
in cells from patients with OA.
4. DISCUSSION
This study was aimed at investigation of the signiﬁcance of
TLRs and their stimulation in contribution to development
of a chronic inﬂammatory process present in patients with
rheumatoid arthritis. We have demonstrated that peripheral
blood mononuclear cells from patients with newly detected
RAspontaneouslygeneratedsigniﬁcantlysmalleramountsof
interleukin-6 and TNFα as compared to monocytes from OA
patients or healthy subjects and that stimulation with LPS
resulted in dramatically higher augmentation of cytokine
production in cells from RA patients as compared to OA
patients.Low-basalproductionofcytokinesisanunexpected
ﬁnding, since these two cytokines are considered to play a
signiﬁcant role in the pathogenesis of joint inﬂammation in
RA; TNFα and IL-6 may stimulate collagenase production,
increase bone resorption and inhibit cartilage regeneration
targeting ﬁbroblasts, osteoclasts, and chondrocytes [28, 29].
Accordingly, previous studies demonstrated increased serum
concentrations and enhanced generation of both cytokines
by mononuclear cells from patients with RA [17–21]. Low
baseline cytokine production in circulating mononuclear
cells may be explained by the fact that we have studied
patients with early detected RA; it is possible that at this
stage of the disease, cells with high potential for cytokine
production have been recruited to the site of inﬂammation
(synovium) and only less active ones are available in
the peripheral circulation. The most striking observation
is a dramatic diﬀerence in response to stimulation with
lipopolysaccharides between mononuclear cells from RA as
compared to OA and healthy controls. Although in patients
with OA and healthy controls LPS induced signiﬁcant (2-7-
fold) increase in production of both cytokines, the increases
in monocytes from RA patients were dramatic: 17 to 31 folds
for TNFα a n d3 0t o4 8f o l d sf o rI L - 6 .T h e s eo b s e r v a t i o n s
indicate that monocytes from patients with early detected
RA, in spite of having low-baseline production of cytokines
demonstrate high potential for cytokine generation upon
stimulation with LPS. LPS is thought to activate cells
through speciﬁc TLR4 receptor which triggers a complex
signaling cascade leading to release of inﬂammatory medi-
ators potentially contributing to development of synovial
inﬂammation. It has been previously demonstrated that
TLR2 and TLR4 ligands enhance cytokine expression in
synovial ﬂuid macrophages from RA patients and induce
catabolic responses in chondrocytes from OA patients [12,
30]. Our observation is in line with putative role of TLR4
receptors in the development of inﬂammatory responses in
rheumatoid arthritis, suggesting that even in patients with
newly detected and not yet pharmacologically treated RA,
circulating inﬂammatory cells (monocytes) can be easily
triggered via TLR4 stimulation to generate proinﬂammatory
cytokines.
15-HETE is an arachidonic acid metabolite generated
by reticulocyte-type B synoviocytes in human rheumatoid
arthritis with potential modulatory eﬀect on inﬂammation
[31, 32]. We have demonstrated for the ﬁrst time that
stimulation of TLR4 but not TLR2 receptors increases
generation of 15-HETE by mononuclear cells from both RA
and OA patients. Although LPS consistently increases 15-
HETE generation in cells from 7 of 7 OA patients, in 4 of 7
patients with RA, the enhancement in 15-HETE generation
by LPS was much higher. Further studies are necessary
to elucidate the potential role of TLR4-triggered 15-HETE
generation in the pathogenesis of RA and OA.
Higher responsiveness of monocytes from RA subjects
to LPS as compared to cells from OA subjects and healthy
controls could be explained by increased expression of
TLR4 receptors on cell surface. Increased expression of
Toll-like receptors on synoviocytes derived from the site
of rheumatoid inﬂammation has been reported [33, 34].
However, information on TLRs expression on peripheral
blood monocytes is less consistent and studies using either
cytoﬂuorometry to detect TLR2 and TLR4 protein or RT-
PCR to detect receptor transcript reported variable results
[29, 30].
In this study, we used quantitative real-time PCR tech-
nique to asses TLR2 and TLR4 expressions in mononuclear
cells. Expression of those 2 types of TLRs was investi-
g a t e di nn o n s t i m u l a t e dc e l l sa sw e l la su n d e rs t i m u l a t o r y
conditions. We have chosen LPS—a TLR4 agonist—and
mix of potent proinﬂammatory cytokines as stimulants
for this part of our experiments. Although the level of
expression of TLR2 gene was not signiﬁcantly diﬀerent
among three groups, expression of TLR4 mRNA was sig-
niﬁcantly decreased in cells from RA or OA patients as
compared of healthy controls. However, these data have
to be interpreted with caution since mRNA was isolated
from total leukocyte population and its measurement might
not reﬂect receptor expression in monocytes, which are
primarily targeted by TLR agonists. Moreover, recent studies
demonstrated dissociation of mRNA expression of Toll-like
receptors from the modulation of TLR-mediated responses,
suggesting that factors other than receptor expression
may be responsible for increased responsiveness of RA
monocytes to TLR ligands [26, 35]. RT-PCR technique
allowed us to analyze TLR mRNA expression in response
to stimulation with cytokine mix (IL1, TNFα and IL-6)
and LPS. While cytokine mix tended to decrease Toll-
like receptors gene expression in all groups studied, LPS
h a dm o r ev a r i a b l ee ﬀects: enhancement of TLR2 receptors
was observed in healthy controls while signiﬁcant depres-
sion of TLR4 expression was noticed in patients with
osteoarthritis. These observations conﬁrm that TLR agonist
similarly to endogenous cytokines may modulate expression
of Toll-like receptors on leukocytes and suggest that this
modulation may vary in cells derived from patients with
diﬀerent form of rheumatic pathology or from healthy per-
sons.
In conclusion, our study demonstrated a signiﬁcant
overresponsiveness of peripheral blood mononuclear cells
from patients with recently diagnosed rheumatoid arthritis
to stimulation with a bacterial product, lipopolysaccharide.
Regulation of TLR expression by cytokine and TLR agonist
may diﬀer in healthy subjects and patients with arthritides.6 Mediators of Inﬂammation
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